125031 ★

The number also serves as a specific article identifier in high-level physics and engineering research:

In the medical field, is the Biologics License Application (BLA) number assigned by the FDA to Neulasta (pegfilgrastim) . 125031

It refers to a notable 2015 paper in Physical Review D titled "Self-similar inverse cascade of magnetic helicity driven by the chiral anomaly" (Phys. Rev. D 92, 125031 ). This research explores how magnetic fields behave in chiral plasmas, which is relevant to understanding the early universe. The number also serves as a specific article

Neulasta is a leukocyte growth factor used to decrease the incidence of infection—manifested by febrile neutropenia—in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs. D 92, 125031 )

Recent supplemental applications (e.g., BLA 125031/S-0202) have added critical safety information to the drug's labeling, including increased risks of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) when used alongside chemotherapy or radiation for breast and lung cancer. Scientific Literature Identifier